Acrivon Therapeutics, Inc. (ACRV)
Nasdaq: ACRV · Pharmaceutical Preparations · Watertown, MA · filing with the SEC since 2021
Filings
140 filings since 2017 beside 208 insider forms · and emerging growth company · read from EDGAR on Nov 13, 2026Due next and emerging growth company
10-Q
Quarterly report for the quarter ending Sep 30, 2026Non-accelerated filers and smaller reporting companies have 45 days after the quarter ends; quarter ends are taken to the month end.
by Nov 14, 2026
10-K
Annual report for the fiscal year ending Dec 31, 2026Non-accelerated filers and smaller reporting companies have 90 days after the fiscal year ends.
by Mar 31, 2027
A deadline is the latest date the SEC's rules allow for its filer category. It is not a forecast of the day the company files. Last time, the results release (8-K item 2.02) came 43 days after the quarter ended. The proxy statement was last filed Apr 30, 2026.
Filings a yearinsider forms included
25251857682
2026 counts to Nov 13, 2026.
Officer or director change (8-K item 5.02): 4 times in the last 36 months, the newest Jun 17, 2026.SEC letters: 4 in the last 36 months, the newest Apr 24, 2024.
Insider forms (3, 4, 5 and 144) are counted each year but not listed here; the people and their trades are on the Ownership tab.
FiledFormWhat it is, in plain wordsPeriodAsk
Jun 17, 2026
8-K items 5.02, 5.07, 9.01
Officer or director change; Shareholder vote · Current report
Mar 19, 2026
8-K items 2.02, 7.01, 9.01
Results released; Investor disclosure (Regulation FD) · Current report
Jan 8, 2026
8-K items 2.02, 7.01, 8.01, 9.01
Results released; Investor disclosure (Regulation FD); Other event · Current report
40 of 140 shown
Every row opens the filing on EDGAR. The plain words are the site's own for each form and each 8-K item; the complete history, insider forms included, is on EDGAR.